Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial - Takeaways - MDSpire

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

  • By

  • Richard E. Pratley

  • Douglas Scott Denham

  • Rupal Trivedi

  • Elaine Watkins

  • Lisa Connery

  • Jennifer Barnes

  • Dongzi Yu

  • Janet Hong

  • Christopher Simard

  • Kimberly Umans

  • Lan Liu

  • Giridhar S. Tirucherai

  • Jing L. Marantz

  • June 8, 2026

  • 0 min

Share

  • 1

    Apitegromab is a monoclonal antibody targeting myostatin, aimed at preserving lean mass during weight loss induced by incretin mimetic therapy.

  • 2

    In the EMBRAZE trial, apitegromab significantly reduced lean mass loss by 1.9 kg compared to placebo, preserving 54.9% of lean mass.

  • 3

    Total body weight loss was similar between apitegromab and placebo, with lean mass loss accounting for a smaller percentage of weight loss in the apitegromab group.

  • 4

    Safety profiles were comparable between apitegromab and placebo, with gastrointestinal adverse events being the most frequently reported.

  • 5

    The study demonstrated that apitegromab effectively preserves lean mass during weight loss, highlighting its potential in pharmacologic weight management.

Original Source(s)

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

  • by Richard E. Pratley, Douglas Scott Denham, Rupal Trivedi, Elaine Watkins, Lisa Connery, Jennifer Barnes, Dongzi Yu, Janet Hong, Christopher Simard, Kimberly Umans, Lan Liu, Giridhar S. Tirucherai, Jing L. Marantz

  • June 8, 2026

Related Content

Association Between Edmonton Obesity Staging System Severity and 90-Day Postoperative Complications After Primary Metabolic and Bariatric Surgery: A Retrospective Cohort Study

IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS

Nationwide prospective cohort study in China: the impact of cumulative modified cardiometabolic index on cardiovascular disease incidence